In contrast to the physician survey, Round 3 of the MRR found that all patients studied had a confirmed wild-type tumour status prior to the initiation of panitumumab treatment; however, this was accounting for both KRAS and RAS testing, and the former was not explicitly asked about in the physician survey, which may in part explain the disparity. The gene discussed is KRAS; the disease is neoplasm.